Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

Hyogo, Hideyuki; Tazuma, Susumu; Arihiro, Koji; Iwamoto, Keiko; Nabeshima, Yoshitaka; Inoue, Motoki; Ishitobi, Tomokazu; Nonaka, Michihiro; Chayama, Kazuaki

doi:10.1016/j.metabol.2008.07.030

Cited by 193 publications

(167 citation statements)

References 52 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…Atorvastatin, a lipid lowering agent of the statins class, led to improved liver steatosis and NAFLD score (Eslami et al, 2013;Foster et al, 2011;Hyogo et al, 2008). Another study including a larger cohort of patients revealed similar results with atorvastatin treatment (Athyros et al, 2006).…”

Section: Treatment Of Mets and Nafldmentioning

confidence: 89%

Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

Asrih

Jornayvaz

2015

Molecular and Cellular Endocrinology

276

196

View full text Add to dashboard Cite

Section: Treatment Of Mets and Nafldmentioning

confidence: 89%

Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

Asrih

Jornayvaz

2015

Molecular and Cellular Endocrinology

276

196

View full text Add to dashboard Cite

“…Likewise, Athyros et al [90] reported an RCT for statins on NAFLD/NASH, but administered statins together with hypertensive drugs and insulin sensitizers, which may have beneficial effects on NAFLD/NASH. Only two pilot studies reported the efficacy of monotherapy with statins against NASH by evaluating the change in hepatic histology, but these studies both involved very small populations [91,92].…”

Section: Metformin Cq: Are Biguanides Effective For Patients With Nafmentioning

confidence: 99%

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

et al. 2015

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease in industrialized countries worldwide, and has become a serious public health issue not only in Western countries but also in many Asian countries including Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease, which often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma. In turn, a large proportion of NAFLD/NASH is the liver manifestation of metabolic syndrome, suggesting that NAFLD/NASH plays a key role in the pathogenesis of systemic atherosclerotic diseases. Currently, a definite diagnosis of NASH requires liver biopsy, though various noninvasive measures are under development. The mainstays of prevention and treatment of NAFLD/NASH include dietary restriction and exercise; however, pharmacological approaches are often necessary.Currently, vitamin E and thiazolidinedione derivatives are the most evidence-based therapeutic options, although the clinical evidence for long-term efficacy and safety is limited. This practice guideline for NAFLD/NASH, established by the Japanese Society of Gastroenterology in cooperation with The Japan Society of Hepatology, covers lines of clinical evidence reported internationally in the period starting from 1983 to January 2012, and each clinical question was evaluated using the GRADE system. Based on the primary release of the full version in Japanese, this English summary provides the core essentials of this clinical practice guideline comprising the definition, diagnosis, and current therapeutic recommendations for NAFLD/NASH in Japan.

show abstract

“…Long-term statin treatment has been associated with significant decreases or even normalization of serum aminotransferase activities in patients with NAFLD and dyslipidemia [39][40][41] . Liver steatosis assessed by either imaging techniques or biopsy was also diminished [40,41] . Interestingly, this benefit appears to be associated with greater vascular risk reduction.…”

Section: Nafld and Lipid-lowering Drugsmentioning

confidence: 99%

Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease

Kostapanos

Kei²,

Elisaf³

2013

WJH

131

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a common health problem with a high mortality burden due to its liver-and vascular-specific complications. It is associated with obesity, high-fat diet as well as with type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS). Impaired hepatic fatty acid (FA) turnover together with insulin resistance are key players in NAFLD pathogenesis. Peroxisome proliferator-activated receptors (PPARs) are involved in lipid and glucose metabolic pathways. The novel concept is that the activation of the PPARα subunit may protect from liver steatosis. Fenofibrate, by activating PPARα, effectively improves the atherogenic lipid profile associated with T2DM and MetS. Experimental evidence suggested various protective effects of the drug against liver steatosis. Namely, fenofibraterelated PPARα activation may enhance the expression of genes promoting hepatic FA β-oxidation. Furthermore, fenofibrate reduces hepatic insulin resistance. It also inhibits the expression of inflammatory mediators involved in non-alcoholic steatohepatitis pathogenesis. These include tumor necrosis factor-α, intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Consequently, fenofibrate can limit hepatic macrophage infiltration. Other liver-protective effects include decreased oxidative stress and improved liver microvasculature function. Experimental studies showed that fenofibrate can limit liver steatosis associated with high-fat diet, T2DM and obesity-related insulin resistance. Few studies showed that these benefits are also relevant even in the clinical setting. However, these have certain limitations. Namely, these were uncontrolled, their sample size was small, fenofibrate was used as a part of multifactorial approach, while histological data were absent. In this context, there is a need for large prospective studies, including proper control groups and full assessment of liver histology.

show abstract

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

Cited by 193 publications

References 52 publications

Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease

Contact Info

Product

Resources

About